JP2008500366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500366A5 JP2008500366A5 JP2007515355A JP2007515355A JP2008500366A5 JP 2008500366 A5 JP2008500366 A5 JP 2008500366A5 JP 2007515355 A JP2007515355 A JP 2007515355A JP 2007515355 A JP2007515355 A JP 2007515355A JP 2008500366 A5 JP2008500366 A5 JP 2008500366A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- aryl
- heteroaryl
- heterocyclic
- alicyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 170
- 239000001257 hydrogen Substances 0.000 claims 170
- 125000001072 heteroaryl group Chemical group 0.000 claims 166
- 125000003118 aryl group Chemical group 0.000 claims 161
- 125000000623 heterocyclic group Chemical group 0.000 claims 126
- 150000002431 hydrogen Chemical class 0.000 claims 120
- 125000002723 alicyclic group Chemical group 0.000 claims 112
- 125000001931 aliphatic group Chemical group 0.000 claims 103
- 239000000203 mixture Substances 0.000 claims 92
- 125000000217 alkyl group Chemical group 0.000 claims 88
- 150000001875 compounds Chemical class 0.000 claims 64
- 229910052736 halogen Inorganic materials 0.000 claims 60
- 150000002367 halogens Chemical class 0.000 claims 60
- 229910052799 carbon Inorganic materials 0.000 claims 43
- 150000001721 carbon Chemical group 0.000 claims 35
- 125000004122 cyclic group Chemical group 0.000 claims 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims 31
- 125000004404 heteroalkyl group Chemical group 0.000 claims 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- 125000002015 acyclic group Chemical group 0.000 claims 11
- 125000002252 acyl group Chemical group 0.000 claims 11
- 230000037396 body weight Effects 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims 7
- 229930195729 fatty acid Natural products 0.000 claims 7
- 239000000194 fatty acid Substances 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 7
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 208000029742 colonic neoplasm Diseases 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000002070 alkenylidene group Chemical group 0.000 claims 5
- 125000001118 alkylidene group Chemical group 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 150000002118 epoxides Chemical class 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 206010003445 Ascites Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000009116 palliative therapy Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 CC(*)(*C(*)C(C(*)C(C(*)C(C12)O)*(C=CC3)=C)*=C)C(*)C(**)*C13[C@]2N Chemical compound CC(*)(*C(*)C(C(*)C(C(*)C(C12)O)*(C=CC3)=C)*=C)C(*)C(**)*C13[C@]2N 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57411404P | 2004-05-25 | 2004-05-25 | |
| US60/574,114 | 2004-05-25 | ||
| PCT/US2005/018603 WO2006001967A2 (en) | 2004-05-25 | 2005-05-25 | Migrastatin analogs in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008136097A Division JP2008273981A (ja) | 2004-05-25 | 2008-05-23 | 癌の処置におけるマイグラスタチンアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500366A JP2008500366A (ja) | 2008-01-10 |
| JP2008500366A5 true JP2008500366A5 (enExample) | 2008-07-10 |
| JP5149001B2 JP5149001B2 (ja) | 2013-02-20 |
Family
ID=35355865
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515355A Expired - Fee Related JP5149001B2 (ja) | 2004-05-25 | 2005-05-25 | 癌の処置におけるマイグラスタチンアナログ |
| JP2008136097A Pending JP2008273981A (ja) | 2004-05-25 | 2008-05-23 | 癌の処置におけるマイグラスタチンアナログ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008136097A Pending JP2008273981A (ja) | 2004-05-25 | 2008-05-23 | 癌の処置におけるマイグラスタチンアナログ |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US8957056B2 (enExample) |
| JP (2) | JP5149001B2 (enExample) |
| WO (1) | WO2006001967A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4719671B2 (ja) | 2003-03-28 | 2011-07-06 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | ミグラスタチンアナログ組成物およびその使用 |
| JP5149001B2 (ja) | 2004-05-25 | 2013-02-20 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | 癌の処置におけるマイグラスタチンアナログ |
| EP1805161B1 (en) * | 2004-09-23 | 2014-05-07 | Sloan-Kettering Institute For Cancer Research | Isomigrastatin analogs in the treatment of cancer |
| PT2109623E (pt) * | 2006-05-22 | 2012-01-12 | Xbiotech Inc | Tratamento de cancro com anticorpos anti-il-1 |
| US20080312317A1 (en) * | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| CA2707009A1 (en) * | 2007-11-21 | 2009-06-04 | Cornell University | Methods for inhibiting fascin |
| CN105467136B (zh) | 2008-05-30 | 2018-02-16 | 埃克斯生物科技公司 | 白细胞介素‑1α抗体及使用方法 |
| WO2010069850A1 (en) * | 2008-12-17 | 2010-06-24 | Sanofi-Aventis | Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| JP6324720B2 (ja) | 2010-06-18 | 2018-05-16 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 関節炎治療 |
| KR102748255B1 (ko) | 2010-08-23 | 2024-12-31 | 엑스바이오테크 인코포레이티드 | 종양성 질병들에 대한 치료 |
| EP2694107B1 (en) | 2011-04-01 | 2018-08-22 | XBiotech, Inc | Treatment for dermatological pathologies |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| JP5975581B2 (ja) * | 2011-04-07 | 2016-08-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | ミグラスタチンおよびその使用 |
| WO2013013240A2 (en) * | 2011-07-21 | 2013-01-24 | Theracrine, Inc. | Macrocyclic compounds and related compositons and methods of use |
| JP6204915B2 (ja) | 2011-09-23 | 2017-09-27 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 悪液質治療 |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| KR20190117579A (ko) | 2017-02-16 | 2019-10-16 | 엑스바이오테크, 인크. | 화농성 한선염의 치료 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL66434C (enExample) * | 1946-12-06 | |||
| FR1264032A (fr) * | 1960-05-06 | 1961-06-19 | Rhone Poulenc Sa | Acide cycloundecanecarboxylique |
| GB1036084A (en) | 1962-02-23 | 1966-07-13 | Upjohn Co | Oxygenated cycloalkanes and the preparation thereof |
| DE1217372B (de) | 1963-01-21 | 1966-05-26 | Rhöne-Poulenc S.A., Paris | Verfahren zur Herstellung von Cycloalkan- und Cycloalkencarbonsäuren bzw. deren Estern |
| DE2934678A1 (de) | 1979-08-28 | 1981-03-12 | Haarmann & Reimer Gmbh, 3450 Holzminden | Cyclopentadecen-8-on-1, verfahren zu seiner herstellung und seine verwendung als riechstoff |
| DE2934683A1 (de) | 1979-08-28 | 1981-03-12 | Haarmann & Reimer Gmbh, 3450 Holzminden | 3-methyl-cyclohexadecen-5-on-1, verfahren zu seiner herstellung und seine verwendung als riechstoff. |
| US4472435A (en) * | 1980-07-31 | 1984-09-18 | Hoffman-La Roche Inc. | Benzophenone derivatives useful in treating heart failure |
| JPS6156146A (ja) | 1984-08-28 | 1986-03-20 | Nippon Mining Co Ltd | 大環状ケトンの製造方法 |
| US4938949A (en) * | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP0374445A1 (fr) | 1988-12-23 | 1990-06-27 | Firmenich Sa | Nouveaux composés cycliques oxygénés, leur utilisation à titre d'ingrédients parfumants, procédé pour leur préparation |
| JPH07138257A (ja) | 1993-11-16 | 1995-05-30 | Taisho Pharmaceut Co Ltd | 骨吸収抑制物質ｂｒ−０４０及びｂｒ−０４２ |
| ZA989885B (en) | 1997-10-31 | 1999-05-05 | Abbott Lab | Use of macrolides for the treatment of cancer and macular degeneration |
| EP0976714A1 (en) | 1998-07-06 | 2000-02-02 | Quest International B.V. | Addition of ketones to alkenes |
| SG80643A1 (en) | 1998-09-03 | 2001-05-22 | Givaudan Roure Int | Methylcyclotetradec-5-en-1-ones |
| JP2000247949A (ja) * | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| JP2001078793A (ja) | 1999-09-10 | 2001-03-27 | Nippon Kayaku Co Ltd | 新規生理活性物質の醗酵法による製造法 |
| JP2001081088A (ja) | 1999-09-10 | 2001-03-27 | Nippon Kayaku Co Ltd | 新規生理活性物質ｎｋ３０４２４類縁体とそれらの製造法および用途 |
| WO2001046451A1 (en) | 1999-12-22 | 2001-06-28 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Migrastatin, process for producing the same and medicinal compositions |
| US6750047B2 (en) * | 2000-08-21 | 2004-06-15 | Kosan Biosciences, Inc. | Fermentation and purification of migrastatin and analog |
| US6660306B2 (en) * | 2000-10-12 | 2003-12-09 | Mickey L. Peshoff | Wound healing compound |
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| AU2002254822A1 (en) | 2001-04-26 | 2002-11-11 | Ecopia Biosciences Inc. | Genes and proteins for the biosynthesis of polyketides |
| EP1264594B1 (en) | 2001-06-08 | 2006-11-29 | Takasago International Corporation | Melanin production inhibitors and skincare products containing such inhibitors |
| JP2003104967A (ja) | 2001-09-28 | 2003-04-09 | Takuma Sasaki | ウロキナーゼ産生阻害剤、血管新生阻害剤、癌転移抑制剤および抗腫瘍剤 |
| JP3973889B2 (ja) | 2001-12-04 | 2007-09-12 | 株式会社ジャパンエナジー | 大環状ケトン化合物の製造方法 |
| EP1534542B1 (fr) | 2002-07-23 | 2007-01-10 | Société de Technologie Michelin | Pneumatique avec ancrage non-lineaire de structure de renfort |
| US7365096B2 (en) | 2002-12-09 | 2008-04-29 | Board Of Regents, The University Of Texas System | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) |
| JP4337815B2 (ja) | 2003-03-19 | 2009-09-30 | 宇部興産株式会社 | ω−シアノアルデヒド化合物の製造法 |
| US20070037783A1 (en) * | 2003-03-28 | 2007-02-15 | Xin-Yun Huang | Migrastatin analogs and uses thereof |
| JP4719671B2 (ja) * | 2003-03-28 | 2011-07-06 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | ミグラスタチンアナログ組成物およびその使用 |
| WO2005019181A1 (en) | 2003-08-19 | 2005-03-03 | Cornell Research Foundation, Inc. | Migrastatin analog cell migration inhibitors |
| JP5149001B2 (ja) | 2004-05-25 | 2013-02-20 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | 癌の処置におけるマイグラスタチンアナログ |
| EP1805161B1 (en) | 2004-09-23 | 2014-05-07 | Sloan-Kettering Institute For Cancer Research | Isomigrastatin analogs in the treatment of cancer |
| CA2707009A1 (en) | 2007-11-21 | 2009-06-04 | Cornell University | Methods for inhibiting fascin |
-
2005
- 2005-05-25 JP JP2007515355A patent/JP5149001B2/ja not_active Expired - Fee Related
- 2005-05-25 US US11/597,678 patent/US8957056B2/en not_active Expired - Fee Related
- 2005-05-25 WO PCT/US2005/018603 patent/WO2006001967A2/en not_active Ceased
-
2008
- 2008-05-23 JP JP2008136097A patent/JP2008273981A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500366A5 (enExample) | ||
| US20250120947A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
| ES2978534T3 (es) | Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer | |
| JP2008523099A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| ES2377975T3 (es) | Composición medicinal que comprende un inhibidor de la HMG-CoA reductasa y un derivado de aminoalcohol como inmunodepresor | |
| RU2011142750A (ru) | Способ лечения путем применения комбинированной терапии | |
| JP2015500209A5 (enExample) | ||
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| ES2746105T3 (es) | Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer | |
| JP2012528858A5 (enExample) | ||
| JP2006523233A5 (enExample) | ||
| JP2006508965A5 (enExample) | ||
| JP2006510658A5 (enExample) | ||
| ES2701123T3 (es) | Derivados de taxano solubles en agua y sus usos | |
| JP2006521407A5 (enExample) | ||
| JP2013504590A5 (enExample) | ||
| CN109956986A (zh) | 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用 | |
| JP2013525290A5 (enExample) | ||
| RU2004111787A (ru) | Ретиноидные агонисты (1), производные алкилмочевины | |
| JP5701387B2 (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
| JP2003535890A5 (enExample) | ||
| SK18332002A3 (sk) | Farmaceutický prostriedok obsahujúci farmaceuticky prijateľný nosič alebo masťový základ a ako aktívnu prísadu derivát akryloyldistamycínu a inhibítor topoizomerázy I a II | |
| WO2025083472A2 (en) | Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation | |
| WO2021097075A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same |